Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BIOCORP and MERCK Sign a Partnership in the Field of Human Growth Hormone

09/16/2021 | 01:30am EDT

BIOCORP and Merck, announce an agreement for the development and supply of a specific version of Mallya device to monitor treatment adherence in the field of HGH. Manufactured in Clermont-Ferrand (France), Mallya is a Bluetooth enabled clip-on device for pen injectors that collects dose and time of each injection and transfers information in real time to a companion software. Mallya is the first in its category to receive the CE-mark (medical device) and commercial versions for insulin pen injectors are already available and distributed in Europe and other geographies. Healthcare companies BIOCORP and Merck will develop a specific version for applications in the field of Human Growth Hormone. The device will help patients (children and teenagers) automatically keep track of their HGH daily injection and monitor adherence with their treatment plan. Following the completion of different milestones, Merck will pay around €3 million for the development of the specific solution. After the development phase, BIOCORP will manufacture the commercial units on behalf of Merck, which will generate additional revenues.


ę S&P Capital IQ 2021
All news about MERCK & CO., INC.
06:46aGilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen o..
BU
10/25ASTRAZENECA : Daiichi Sankyo in Clinical Trial Collaboration to Evaluate Datopotamab Derux..
MT
10/25Health Care Stocks Higher in Monday Trading Amid Large Gains by Biotechs
MT
10/25XERIS BIOPHARMA : Merck in Collaboration Deal With Option to License ' XeriJect - Shares J..
MT
10/25MERCK : Reports Positive Results From Phase 3 Trials Evaluating Combination HIV-1 Therapy
MT
10/25Health Care Stocks Mixed Premarket Monday
MT
10/25MERCK : European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as..
AQ
10/25MERCK : EU Medicines Regulator Starts Rolling Review For Merck And Co.'s COVID-19 Drug
MT
10/25MERCK : Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investi..
BU
10/25Merck & Co., Inc. Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evalu..
CI
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 248 M - -
Net income 2021 13 308 M - -
Net Debt 2021 17 557 M - -
P/E ratio 2021 17,2x
Yield 2021 3,17%
Capitalization 207 B 207 B -
EV / Sales 2021 4,65x
EV / Sales 2022 4,08x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 81,66 $
Average target price 94,79 $
Spread / Average Target 16,1%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-0.17%206 712
JOHNSON & JOHNSON4.26%431 938
ROCHE HOLDING AG15.61%338 364
NOVO NORDISK A/S59.69%243 351
PFIZER, INC.17.25%241 929
ELI LILLY AND COMPANY45.14%222 158